Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19088593 | 0.85 | USP2 (0.33) | USP2SMN1; SMN2SPHK1 | |
| SCHEMBL28115632 | 0.79 | MAPK1 (0.38) | USP2SMN1; SMN2RECQLALDH1A1MAPT | |
| SCHEMBL28282841 | 0.78 | TSHR (0.47) | SMN1; SMN2RECQLHPGDALDH1A1LMNA | |
| SCHEMBL31197138 | 0.76 | USP2 (0.53) | USP2SMN1; SMN2RECQLCTSKCHRM2 | |
| SCHEMBL9852425 | 0.74 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDALDH1A1LMNA | |
| SCHEMBL26884952 | 0.72 | USP2 (0.42) | USP2SMN1; SMN2RECQLCTSKCHRM2 | |
| SCHEMBL2634417 | 0.72 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL16838402 | 0.72 | USP2 (0.57) | USP2SMN1; SMN2RECQLHPGDEPHX2 | |
| SCHEMBL31105190 | 0.72 | USP2 (0.49) | USP2SMN1; SMN2RECQLCTSKCHRM2 | |
| SCHEMBL16413908 | 0.72 | USP2 (0.49) | USP2SMN1; SMN2RECQLCTSKCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118541362-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-08-23 | — | — | CN | claimed |
| US-20260115330-A1 | RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250100997-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-03-27 | — | — | US | disclosed |
| US-12246081-B2 | Deodorant compositions | CONOPCO, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| CN-119192008-A | Preparation method of L-vinylglycine hydrochloride | 上海海皋科技有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119192008-A | Preparation method of L-vinylglycine hydrochloride | 上海海皋科技有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4463448-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2024-11-20 | — | — | EP | disclosed |
| CN-118878461-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118541362-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118159548-A | Antiviral compounds | 安力高医药股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| CN-1561332-A | Preparation of HIV protease inhibitors | HOFFMANN LA ROCHE (CH) | 2005-01-05 | — | — | CN | disclosed |
| EP-1404664-A1 | AMINEDIOLS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003006453-A1 | AMINEDIOLS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| CN-1379762-A | Beta substituted metalloprotease inhibitors | PROCTER & GAMBLE (US) | 2002-11-13 | — | — | CN | disclosed |
| EP-1140849-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1073672-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000040560-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
| WO-1999057135-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115330-A1 | RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS | KLK3, BRDT, BPHL | USP2 755/4885SMN1; SMN2 3766/4885RECQL 3973/4885 |
| US-12246081-B2 | Deodorant compositions | DHODH, STS, DDT | USP2 541/4885SMN1; SMN2 3650/4885RECQL 1200/4885 |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | USP2 2468/4885SMN1; SMN2 1149/4885RECQL 139/4885 |
| US-20250100997-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | USP2 3820/4885SMN1; SMN2 3267/4885RECQL 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.